Clinical Trials Logo
  1. Home
  2. Malignant Melanoma
  3. NCT04924413
  4. Details
NCT04924413 Clinical Trial

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Malignant Melanoma Clinical Trial

Official title:
L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT04924413
Other study ID # HenanCH L-TIL Melanoma
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 1, 2021
Est. completion date December 31, 2025

Study information
Verified date May 2021
Source Henan Cancer Hospital
Contact Quanli Gao, Ph.D
Phone 0371-65587483
Email zlyygql0855@zzu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the safety and effectiveness of liquid tumor infiltrating lymphocytes (L-TIL) combined with tislelizumab as the first-line treatment in patients with advanced malignant melanoma. This study plan to include stage III or IV unresectable or metastatic cutaneous or acral malignant melanoma patients, treat with L-TIL 4 cycles with each infusion (3 -10) x10*9/m2 cells, combined with tislelizumab 200mg, iv, Q3W. It is expected that 30 patients will be enrolled in this study.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 30
Est. completion date December 31, 2025
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Pathological confirmed melanoma 2. Advanced stage confirmed by radiological examination 3. Untreated 4. ECOG PS 0-1 6. Good organ function 7. No other severe diseases such as autoimmune disease, organ transplant, chronic infection. 8. Other tumor disease. Exclusion Criteria: 1. Symptomatic brain metastases 2. Active infection 3. Active HBV or HCV infection 4. HIV infection 5. Autoimmune disease 6. Sensitive to drug or ingredients 7. Severe mental disorders 8. Sever disfunction of heart, liver and kidney

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Tislelizumab
PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Quanli Gao

References & Publications (1)

Li T, Zhao L, Yang Y, Wang Y, Zhang Y, Guo J, Chen G, Qin P, Xu B, Ma B, Zhang F, Shang Y, Li Q, Zhang K, Yuan D, Feng C, Ma Y, Liu Z, Tian Z, Li H, Wang S, Gao Q. T Cells Expanded from PD-1(+) Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes. Cancer Res. 2021 Apr 15;81(8):2184-2194. doi: 10.1158/0008-5472.CAN-20-2300. Epub 2021 Jan 6. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Efficacy (ORR) The objective response rate (ORR) at 8 weeks from baseline. 8 weeks
Primary Efficacy (ORR) The objective response rate (ORR) at 16 weeks. 16 weeks
Primary Efficacy (DOR) The duration of response (DOR) at 1-year. 1 year
Primary Efficacy (DOR) The duration of response (DOR) at 2-year. 2 years
Primary Safety The adverse events followed by treatment. 2 years
Secondary Progression free survival (PFS) The PFS rate at 1 year. 1 year
Secondary Progression free survival (PFS) The PFS rate at 2-year. 2 years
Secondary Overall survival (OS) The OS rate at 1 year. 1 year
Secondary Overall survival (OS) The OS rate at 2-year. 2 years
See also
  Status Clinical Trial Phase
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Active, not recruiting NCT04074096 - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis Phase 2
Completed NCT02935790 - Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab Phase 1
Recruiting NCT05478876 - Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract N/A
Completed NCT01211262 - Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma Phase 1
Recruiting NCT03649529 - Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy Early Phase 1
Completed NCT03278665 - 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy Phase 1/Phase 2
Completed NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Completed NCT01455259 - Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors Phase 1/Phase 2
Completed NCT00978913 - Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma Phase 1
Completed NCT00232726 - Clinical Study of Previously Untreated Patients With Malignant Melanoma Phase 2
Completed NCT00336986 - Efficacy Study of IL-21 to Treat Metastatic Melanoma Phase 2
Completed NCT00350597 - GM-CSF as Adjuvant Therapy of Melanoma Phase 2
Completed NCT02523313 - Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED Phase 2
Completed NCT03545334 - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study N/A
Completed NCT04253574 - Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
Completed NCT00179608 - Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy Phase 1
Terminated NCT00104884 - FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Phase 2

External Links